The National Times - Pfizer sees high demand for Covid-19 pill as profits jump

Pfizer sees high demand for Covid-19 pill as profits jump


Pfizer sees high demand for Covid-19 pill as profits jump
Pfizer sees high demand for Covid-19 pill as profits jump / Photo: © AFP/File

Pfizer executives said Tuesday they are confident of strong demand for the company's Covid-19 antiviral treatment amid easing pandemic rules as the big drugmaker reported another round of strong earnings.

Change text size:

The US pharmaceutical giant, reporting surging first-quarter profits based on a big jump in revenues from its Covid-19 vaccine, said its Paxlovid treatment for the virus would be a valuable means for governments to limit the severity of outbreaks as they ease social distancing and masking rules.

Pfizer Chief Executive Albert Bourla said the company is seeing "very strong signs of increasing demand for Paxlovid as it remains one of the best tools we have."

Citing rising vaccine fatigue, Bourla said the company is also focused on a Covid-19 vaccine booster that provides immunity for a year.

"People are tired of the repeated booster, so it is extremely important to come to a vaccine that could be a yearly vaccine," Bourla told analysts on a conference call, adding that while the company has made progress on this front, "it's not technically easy to achieve."

"There's a tremendous pressure across the world to get our lives back," Bourla said of the social and political impetus to ease pandemic rules. "As a result of these things it's very clear that we will have waves" of Covid-19.

- 'Rebound' risk -

The US drugmaker reported first-quarter profits of $7.9 billion, up 61 percent, based on a 77 percent surge in revenues to $25.7 billion.

Pfizer lowered its full-year adjusted profits by 10 cents to $6.25 to $6.45 a share, due in part to currency movements.

But the company confirmed its full-year revenue forecast of about $100 billion, which is an approximately 23 percent increase on the 2021 level. More than half the revenues are expected to come from the Covid-19 vaccine and therapeutic.

Pfizer, which has shipped some 3.4 billion doses of vaccine to 179 countries, has won regulatory approval for its shot in most age groups, but continues to study its use in children younger than five.

In the first quarter, Paxlovid took in $1.5 billion in global sales. But Pfizer expects 2022 sales of the medicine of $22 billion as it ramps up production and distribution.

The company expects to produce 120 million courses of the Paxlovid oral pills in 2022, with distribution programs scaling up in the United States and other markets.

The treatment has received emergency or conditional approval in 40 countries so far, the company said.

"What we are seeing is... there is demand for this product," said Pfizer biopharmaceuticals group president Angela Hwang, citing the removal of mask mandates as a factor in spreading cases.

"What we're also seeing is that we don't have any inventory on hand," Hwang said. "Every dose that we produce is being shipped out."

Pfizer executives said they were researching "rebound" Covid-19 cases in which some patients who took Paxlovid have reported renewed symptoms.

But company officials said the data thus far suggests that the amount of cases is small and may have to do with unusual patient characteristic rather than the drug itself.

The World Health Organization last month "strongly recommended" the antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalization.

But WHO said it was "extremely concerned" that low- and middle-income countries would be "pushed to the end of the queue" amid tight global supplies.

Shares of Pfizer rose 1.7 percent to $49.17 in afternoon trading.

S.Collins--TNT

Featured

Langley Businesses Navigate Tariff Pressures Amid Holiday Shopping Push

Independent businesses in Langley are facing heightened financial pressures from recent tariff implementations as they navigate the crucial holiday shopping period. While supply chain disruptions threaten inventory and pricing, local advocates highlight that spending at community retailers recirculates significantly more wealth within the region than purchases made through multinational or online platforms.

ALIX LASERS shareholders remove Michael Sobitsch as managing director in view of the circumstances

In an interview with BERLINER TAGESZEITUNG, the shareholders of Alix Lasers GmbH in Austria said that, after acquiring 100 per cent of the company’s shares, they removed Michael Sobitsch from his position as managing director yesterday, 19 November 2026, in Vienna, Austria. In view of the circumstances, they removed him from office with immediate effect, without granting him discharge for his tenure as managing director.

Analysts Identify Key Metal Stocks Amid 38% Commodity Slide

With silver, copper, and gold prices falling up to 38% from recent peaks due to global economic concerns, technical analysts at Angel One and SAMCO Securities have identified specific trading opportunities in major metal equities. The firms' research highlights both bearish setups for stocks like Hind Copper and SAIL, alongside potential bullish breakouts for APL Apollo Tubes and Jindal Stainless.

Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year

Saudi Arabia's Public Investment Fund (PIF) has been named the world’s most valuable sovereign wealth fund brand for the third consecutive year, according to a new assessment by Brand Finance. The ranking highlights the fund's growing global influence and financial strength as it advances its strategic objectives under Vision 2030.

Change text size: